Software · NYSE: VEEV
Veeva Systems earnings: results, call transcripts & KPI history
2 quarters · fiscal year ends January · next results expected around 19 Nov 2026
Latest: Q2 FY2027
Veeva's Vault CRM had its best quarter ever, with 12 top 20 biopharma commitments, while Veeva Falcon agentic AI for clinical, regulatory and safety moves toward first go-lives.
Veeva's push into AI-driven applications gained traction. Vault CRM has more than 180 customers live, including five top 20 biopharmas, and a top 20 biopharma rolled out Vault CRM with the Agentic Call Report to its full U.S. field team. Development Cloud and Quality Cloud saw broad adoption: a large biopharma selected Veeva EDC, Veeva Safety passed 100 customers, and Quality added more than 30 new customers. Veeva also acquired Copli and launched Veeva Falcon MLR.
Quarters
KPI history
Fourth quarter worked out from the annual figure.
Data
| Q3 FY25 | $699.2M |
| Q4 FY25 | $720.9M * |
| Q1 FY26 | $759.0M |
| Q2 FY26 | $789.1M |
| Q3 FY26 | $811.2M |
| Q4 FY26 | $836.0M * |
| Q1 FY27 | $882.9M |
| Q2 FY27 | $928.0M |
Data
| Q3 FY25 | $1.13 |
| Q1 FY26 | $1.37 |
| Q2 FY26 | $1.19 |
| Q3 FY26 | $1.40 |
| Q1 FY27 | $1.57 |
| Q2 FY27 | $1.66 |
Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.
Data
| Q3 FY25 | 25.9% |
| Q4 FY25 | 26.1% |
| Q1 FY26 | 30.8% |
| Q2 FY26 | 24.8% |
| Q3 FY26 | 29.7% |
| Q4 FY26 | 29.4% |
| Q1 FY27 | 30.9% |
| Q2 FY27 | 29.6% |
| Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | Q2 FY27 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $699.2M | $720.9Md | $759.0M | $789.1M | $811.2M | $836.0Md | $882.9M | $928.0M |
| Gross margin | 75.1% | 74.9% | 77.1% | 75.3% | 75.4% | 74.5% | 75.0% | 75.0% |
| Operating income | $181.4M | $188.4Md | $233.7M | $195.9M | $240.9M | $245.9Md | $273.1M | $275.0M |
| Operating margin | 25.9% | 26.1% | 30.8% | 24.8% | 29.7% | 29.4% | 30.9% | 29.6% |
| Net income | $185.8M | $195.6Md | $228.2M | $200.3M | $236.2M | $244.2Md | $260.9M | $273.4M |
| Diluted EPS | $1.13 | — | $1.37 | $1.19 | $1.40 | — | $1.57 | $1.66 |
| Operating cash flow | $164.1Md | $69.5Md | $877.2M | $238.4Md | $192.8Md | $106.8Md | $1.1B | $238.7Md |
| R&D expense | $172.4M | $181.5Md | $184.0M | $192.7M | $191.9M | $198.8Md | $208.3M | $222.9M |
From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.
10-K and 10-Q filings
- 27 Aug 202610-Q for the period ended 31 Jul 2026SEC ↗
- 5 Jun 202610-Q for the period ended 30 Apr 2026SEC ↗
- 20 Mar 202610-K for the period ended 31 Jan 2026SEC ↗
- 21 Nov 202510-Q for the period ended 31 Oct 2025SEC ↗
- 29 Aug 202510-Q for the period ended 31 Jul 2025SEC ↗
- 2 Jun 202510-Q for the period ended 30 Apr 2025SEC ↗
- 24 Mar 202510-K for the period ended 31 Jan 2025SEC ↗
- 9 Dec 202410-Q for the period ended 31 Oct 2024SEC ↗